1204975-11-0

Usage

Uses

Used in Pharmaceutical Industry:
(R)-4-(6-Benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester is used as a potential pharmaceutical compound for its unique structure and functional groups, which may offer novel therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester can be utilized as a key intermediate or building block for the synthesis of other complex molecules with potential applications in various industries.
Further research and study are required to fully understand the properties and potential uses of (R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester in different fields, as its unique structure and functional groups may offer new opportunities for innovation and development.

Upstream product

• 1204978-02-8 3-benzyl-6-chloro-4,5-dimethylpyridazine 
• 34584-69-5 3,6-dichloro-4,5-dimethylpyridazine 
• 62673-31-8 benzyl(bromo)zinc 
• 1204978-10-8 3-benzyl-4,5-dimethyl-6-((R)-3-methyl-piperazin-1-yl)-pyridazine 
• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 

Downstream Products

• 1204975-59-6 1-[(R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl]-ethanone 
• 1204975-42-7 LEQ-506 
• 1204976-17-9 (R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid 
• 1204976-08-8 (R)-3-(5-(4-(6-benzyl-4,5-dimethylpyridazin-3-yl)-2-methylpiperazin-1-yl)pyrazin-2-yl)pentan-3-ol 

Relevant academic research and scientific papers

Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened

First disclosure: Continued optimization provided a novel type of Smoothened (Smo) antagonist based on a pyridazine core. The compound, NVP-LEQ506, currently in phaseI clinical trials, combines high intrinsic potency and good pharmacokinetic properties resulting in excellent efficacy in rodent tumor models of medulloblastoma. Activity against a Smo mutant conferring resistance observed in a previous clinical trial with a competitor compound suggests additional therapeutic potential.

Organic Compounds as Smo Inhibitors

The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action involve methods of inhibiting tumorigenesis, tumor growth and tumor survival using agents that inhibit the Hedgehog and Smo signaling pathway.